Country: Canada
Language: English
Source: Health Canada
SILDENAFIL (SILDENAFIL CITRATE)
LABORATOIRE RIVA INC.
G04BE03
SILDENAFIL
50MG
TABLET
SILDENAFIL (SILDENAFIL CITRATE) 50MG
ORAL
4/8/30
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0136261002; AHFS:
CANCELLED PRE MARKET
2016-02-04
PRODUCT MONOGRAPH PR RIVA-SILDENAFIL Sildenafil tablets (as sildenafil citrate) 25 mg, 50 mg and 100 mg cGMP-Specific Phosphodiesterase Type 5 Inhibitor Treatment of Erectile Dysfunction LABORATOIRE RIVA INC. DATE OF PREPARATION: 660 Boul. Industriel December 18, 2012 Blainville Québec J7C 3V4 SUBMISSION CONTROL NO: 160584 _Riva-SILDENAFIL V Product Monograph Page 2 of 46_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS......................................................................................... 4 ADVERSE REACTIONS .......................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 14 OVERDOSAGE ....................................................................................................................... 15 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY................................................................................................. 19 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 19 PART II: SCIENTIFIC INFORMATION ..................................................................................... 21 PHARMACEUTICAL INFOR Read the complete document